The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Multiple Sclerosis: A Review
Open accessAbstract
5and 50% of patients will need help walking within 15 years after the onset of the disease. 6 Twice as many women are affected as men, and persons of Northern European descent appear to be at highest risk for MS. 2,7 The disease is diagnosed on the basis of clinical findings and supporting evidence from ancillary tests, such as magnetic resonance imaging (MRI) of the brain and examination of the cerebrospinal fluid (CSF). MS typically presents in adults 20 to 45 years of age; occasionally, it presents in childhood or late middle age. 7
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Cited by
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738
N-Acetylcysteine (NAC): Impacts on Human Health
Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M. D., & Goulart, M. O. F. (2021) · Antioxidants · doi:10.3390/antiox10060967 · Cited by 526
MMP‐9 in translation: from molecule to brain physiology, pathology, and therapy
Vafadari, B., Salamian, A., & Kaczmarek, L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13415 · Cited by 382
Old Drugs as New Treatments for Neurodegenerative Diseases
Durães, F., Pinto, M., & Sousa, E. (2018) · Pharmaceuticals · doi:10.3390/ph11020044 · Cited by 343
Physical activity and autoimmune diseases: Get moving and manage the disease
Sharif, K., Watad, A., Bragazzi, N. L., Lichtbroun, M., Amital, H., & Shoenfeld, Y. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.010 · Cited by 324
Eid, R., Arab, N. T. T., & Greenwood, M. T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.002 · Cited by 288
Digital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 272
Depression in multiple sclerosis
Patten, S. B., Marrie, R. A., & Carta, M. G. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1322555 · Cited by 262
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152
Giacoppo, S., Bramanti, P., & Mazzon, E. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.06.015 · Cited by 92
Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis
Eftekharian, M. M., Noroozi, R., Sayad, A., Sarrafzadeh, S., Toghi, M., Azimi, T., Komaki, A., Mazdeh, M., Inoko, H., Taheri, M., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.08.045 · Cited by 43
Zhang, S., Su, Y., Ying, Z., Guo, D., Pan, C., Guo, J., Zou, Z., Wang, L., Zhang, Z., Jiang, Z., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819917116 · Cited by 43
Remyelination in multiple sclerosis from the miRNA perspective
Maciak, K., Dziedzic, A., & Saluk, J. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1199313 · Cited by 28
Glial cells as therapeutic targets in progressive multiple sclerosis
Wilbanks, B., Maher, L., & Rodriguez, M. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1614443 · Cited by 17
Metadata
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1973-05-19
- Volume
- 2
- Issue
- 5863
- Pages
- 432-432
- ISSN
- 0007-1447 (ISSN-L)
- 1468-5833
- OpenAlex
- W2108718949
- Cited by
- 488
- References
- 47
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.